Investor Relations

About AVROBIO

 

Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by its industry leading plato® gene therapy platform, our foundation designed to deliver gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario.

 

Sign up for email alerts

Stock Chart


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events & Presentations

Our News Latest press releases

Oct 20, 2021

AVROBIO to Present at the Jefferies Virtual Gene Therapy/Editing Summit

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 20, 2021-- AVROBIO, Inc . (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will present at the Jefferies Virtual Gene

Read More

Oct 19, 2021

AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1

No adverse events or serious adverse events related to drug product in 14 patients treated in Phase 1 and 2 Fabry disease trials and Phase 1/2 Gaucher disease trial Post-gene therapy administration safety data out 4½ years for first patient dosed AVROBIO leads way with new industry-leading

Read More

Oct 06, 2021

AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress

New safety data to be reported from clinical trials in Fabry disease and Gaucher disease type 1 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 6, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today

Read More

See All

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.